Skip to main content
Top
Published in: Clinical and Translational Oncology 11/2013

01-11-2013 | Special Article

New sequencing technologies

Author: Ivo Glynne Gut

Published in: Clinical and Translational Oncology | Issue 11/2013

Login to get access

Abstract

Nucleic acid sequencing is one of the most important tools of biological research with very broad application. Four generations of DNA sequencing technologies can be distinguished by their nature and the kind of output they provide. Sanger sequencing dominated for 30 years and was the workhorse of the Human Genome Project. In 2005 the first 2nd generation sequencer was presented with an output orders of magnitude higher than Sanger sequencing and dramatically reduced cost per base. Currently, we are at the dawn of third generation with nanopore systems that are being developed for DNA sequencing. Meanwhile, the field is broadening applications that complement first, second and third generation sequencing systems to get high-resolution genetic information and fourth generation sequencing is on the horizon. Second generation nucleic acid sequencers are systematically applied in many large-scale international projects such as the International Cancer Genome Consortium and the International Human Epigenome Project.
Literature
1.
go back to reference Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA. 1977;74(12):5463–7.PubMedCrossRef Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA. 1977;74(12):5463–7.PubMedCrossRef
2.
go back to reference Kircher M, Kelso J. High-throughput DNA sequencing—concepts and limitations. BioEssays. 2010;32(6):524–36.PubMedCrossRef Kircher M, Kelso J. High-throughput DNA sequencing—concepts and limitations. BioEssays. 2010;32(6):524–36.PubMedCrossRef
3.
go back to reference International Human Genome Sequencing, C. Finishing the euchromatic sequence of the human genome. Nature. 2004;431(7011):931–45. International Human Genome Sequencing, C. Finishing the euchromatic sequence of the human genome. Nature. 2004;431(7011):931–45.
4.
go back to reference McGinn S, Gut IG. DNA sequencing—spanning the generations. N Biotechnol. 2013;30(4):366–72. McGinn S, Gut IG. DNA sequencing—spanning the generations. N Biotechnol. 2013;30(4):366–72.
5.
6.
7.
go back to reference Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, Bemben LA, et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature. 2005;437(7057):376–80.PubMed Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, Bemben LA, et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature. 2005;437(7057):376–80.PubMed
8.
go back to reference Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, Brown CG, et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature. 2008;456(7218):53–9.PubMedCrossRef Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, Brown CG, et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature. 2008;456(7218):53–9.PubMedCrossRef
9.
go back to reference Valouev AJ, Ichikawa T, Tonthat J, Stuart S, Ranade S, Peckam H, et al. A high-resolution, nucleosome position map of C. elegans reveals a lack of universal sequence-dictated positioning. Genome Res. 2008;18(7):1051–63.PubMedCrossRef Valouev AJ, Ichikawa T, Tonthat J, Stuart S, Ranade S, Peckam H, et al. A high-resolution, nucleosome position map of C. elegans reveals a lack of universal sequence-dictated positioning. Genome Res. 2008;18(7):1051–63.PubMedCrossRef
10.
go back to reference Rothberg JM, Hinz JM, Rearick TM, Schultz J, Mileski W, Davey M, et al. An integrated semiconductor device enabling non-optical genome sequencing. Nature. 2011;475(7356):348–52.PubMedCrossRef Rothberg JM, Hinz JM, Rearick TM, Schultz J, Mileski W, Davey M, et al. An integrated semiconductor device enabling non-optical genome sequencing. Nature. 2011;475(7356):348–52.PubMedCrossRef
11.
go back to reference Schadt EE, Turner S, Kasarskis A. A window into third-generation sequencing. Hum Mol Genet. 2010;19(R2):R227–40.PubMedCrossRef Schadt EE, Turner S, Kasarskis A. A window into third-generation sequencing. Hum Mol Genet. 2010;19(R2):R227–40.PubMedCrossRef
12.
go back to reference Eid J, Fehr A, Gray J, Luong K, Lyle J, Otto G, et al. Real-time DNA sequencing from single polymerase molecules. Science. 2009;323(5910):133–8.PubMedCrossRef Eid J, Fehr A, Gray J, Luong K, Lyle J, Otto G, et al. Real-time DNA sequencing from single polymerase molecules. Science. 2009;323(5910):133–8.PubMedCrossRef
13.
go back to reference Clarke J, Wu HC, Jayasinghe L, Patel A, Reid S, Bayley H. Continuous base identification for single-molecule nanopore DNA sequencing. Nat Nanotechnol. 2009;4(4):265–70.PubMedCrossRef Clarke J, Wu HC, Jayasinghe L, Patel A, Reid S, Bayley H. Continuous base identification for single-molecule nanopore DNA sequencing. Nat Nanotechnol. 2009;4(4):265–70.PubMedCrossRef
14.
go back to reference Larsson C, Grundberg I, Soderberg O, Nilsson M. In situ detection and genotyping of individual mRNA molecules. Nat Methods. 2010;7(5):395–7.PubMedCrossRef Larsson C, Grundberg I, Soderberg O, Nilsson M. In situ detection and genotyping of individual mRNA molecules. Nat Methods. 2010;7(5):395–7.PubMedCrossRef
Metadata
Title
New sequencing technologies
Author
Ivo Glynne Gut
Publication date
01-11-2013
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 11/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-013-1073-6

Other articles of this Issue 11/2013

Clinical and Translational Oncology 11/2013 Go to the issue

Educational Series – BLUE SERIES

Has discovery-based cancer research been a bust?

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine